Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus- like particles in a case-control study of cervical squamous intraepithelial lesions

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1424-1428

  Wideroff, L ^a   Schiffman, M ^a   Haderer, P ^h   Armstrong, A ^h   Greer, C E ^d   Manos, M M ^d,f   Burk, R D ^e   Scott, D R ^c   Sherman, M E ^b   Schiller, J T ^a   Hoover, R N ^a   Tarone, R E ^a   Kirnbauer, R ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c KAISER PERMANENTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f DIVISION OF RESEARCH   (United States)

^g Universitatsklinik fur Dermatologie   (Austria)

^h EPN 313 MSC 7344 ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; DNA DETERMINATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SERODIAGNOSIS; UTERINE CERVIX CARCINOMA IN SITU; VIRUS PARTICLE; VIRUS TYPING; WART VIRUS;

ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS REACTIONS; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRION;

EID: 0032703640     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315055     Document Type: Article

References (22)

1. 1. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
2. 2. Kirnbauer R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996;39:54-67.
3. 3. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of seroreactivity to HPV 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-30.
4. 4. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type-16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
5. 5. De Gruijl, Bontkes HJ, Walboomers JMM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:630-8.
6. 6. Sasagawa T, Yamazaki H, Dong YZ, Satake S, Tateno M, Inoue M. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer 1998;75:529-35.
7. 7. Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
8. 8. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173:1394-8.
9. 9. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997;89:1293-9.
10. 10. Olsen A, Dillner J, Gjøen K, Sauer T, Ørstavik I, Magnus P. A population-based case-control study of human papillomavirus-type 16 seropositivity and incident high-gradee dysphsia of the uterine cervix. Int J Cancer 1996;68:415-9.
11. 11. Shah KV, Viscidi KP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997;6:233-7.
12. 12. Wideroff L, Schiffman MH, Hoover R, et al. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type-16 virus-like particles in cervical HPV-16 DNA-positive and -negative women. J Infect Dis 1996;174:937-43.
13. 13. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomaviruses in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
14. 14. Chua KL, Wiklund F, Lenner P, et al. A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996;68:54-9.
15. 15. Wang Z, Konya J, Avall-Lundkvist E, Sapp M, Dillner J, Dillner L. Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 1997;52:436-10.
16. 16. Rose RC, Bonnez W, Da Rin C, McCanee DJ, Reichman RC. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 1994;75:2445-9.
17. 17. Strickler HD, Hildesheim A, Viscidi RP, et al. Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays. J Clin Microbiol 1997;35:1751-6.
18. 18. Bauer HM, YiTing MS, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
19. 19. Manos MM, Waldman J, Zhang TY, et al. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis 1994;170:1096-9.
20. 20. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP61 primer systems. J Clin Microbiol 1997;35:1304-10.
21. 21. Thomas DG, Gart JJ. Improved und extended exact and asymptotic methods for the combination of 2x2 tables, version 2.04. Comput Biomed Res 1992;25:75-84.
22. 22. af Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998;177: 1710-4.